A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants >/=;18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER study)

Disease Sites:

Sarcoma

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Blinded Drug, Ivosidenib

Principal Investigator(s):

Davis, Elizabeth

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

05-27-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTSAR23242

National Clinical Trial ID:

NCT06127407

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available